×

Biotech and Pharmaceuticals Life Sciences

  • Jan 25- Novartis, lagging some other big drugmakers in the first wave of immunotherapy drugs that are revolutionising cancer treatment, hopes to catch up by focusing on the next wave of immune system-boosting medicines. Setting out its research objectives in slides for a press conference on Wednesday, it said it aimed for "a leadership position in oncology" by...

  • Merck will make an initial payment of $625 million to Bristol and Japan's Ono. Bristol and Ono, which co-developed the first PD-1 antibody called Opdivo, filed the suit against Merck in September 2014, alleging that its sale of Keytruda, also a PD-1 antibody, infringed their patents in markets including the United States, parts of Europe, Australia and Japan.

  • President Donald Trump's policies could lead to more violent stock market movements, something prominent hedge fund manager Lee Ainslie said could help his portfolio rebound after a lousy 2016.. Ainslie's $11 billion Maverick Capital missed out on a rally sparked by Trump's unexpected election in November and ended the year with double digit losses in its...

  • Shares of Bristol, which closed at $55.49 on the New York Stock Exchange, were down 6.2 percent at $52.08 after hours. The pharmaceutical company cited "a review of data available at this time" for the decision to hold off on filing for Food and Drug Administration approval of the combination of its cancer drugs Opdivo and Yervoy. Merck said the FDA would decide by...

  • WASHINGTON, Jan 18- President-elect Donald Trump's nominee to head the U.S. Department of Health and Human Services defended his stock holdings and proposals to dismantle Obamacare on Wednesday, saying Americans would not suddenly lose health insurance. Price told the Senate Committee on Health, Education, Labor and Pensions, one of two that oversee the...

  • *Fed minutes show U.S. policymakers eyeing faster rate hikes. Jan 4- U.S. shares ended higher on Wednesday even after minutes from the Federal Reserve's December meeting showed concerns that quicker economic growth under President-elect Donald Trump could require faster interest rate increases to ward off inflation. "Clearly, some of the members on the...

  • *Fed minutes show policymakers eyeing faster rate hikes. Jan 4- U.S. shares ended higher on Wednesday even after minutes from the Fed's December meeting showed concerns that quicker economic growth under President-elect Donald Trump could require faster interest-rate increases to ward off inflation. "Clearly, some of the members on the committee are taking a...

  • *Fed minutes show policymakers eyeing faster rate hikes. Jan 4- Wall Street held onto gains on Wednesday after minutes from the Fed's December meeting showed policymakers were concerned that quicker economic growth under President-elect Donald Trump could require faster interest-rate increases. "Clearly, some of the members on the committee are taking a...

  • Capsugal purchase will create value: Lonza CEO

    Lonza CEO, Richard Ridinger, talks about the company’s strategic plans going into 2017, while commenting on Donald Trump’s influence on the sector.

  • Capsugel deal isn’t a short-term move: Lonza CEO

    Lonza CEO, Richard Ridinger, explains why the acquisition of Capsugel is “the perfect fit” for the pharmaceutical manufacturer.

  • In vitro fertilisation (IVF) being performed by a fertility doctor (right).

    A common chemotherapy drug has been found to help produce more eggs in a woman's ovaries, indicating a possible solution for low fertility.

  • Honoree Bob Dylan speaks onstage at the 25th anniversary MusiCares 2015 Person Of The Year Gala honoring Bob Dylan at the Los Angeles Convention Center on February 6, 2015 in Los Angeles, California.

    American winners of the prize will find that they're making less than any winner since 1988.

  • Google invests $4 billion a year on

    James Gautrey, global sector specialist for technology and telecoms at Schroders, approves of Google's ability to invest in riskier ventures.

  • Scientists create life without an egg

    Biologists were able to breed baby mice by injecting sperm into a non-viable type of embryo.

  • Executive Edge: Science behind earworms

    David Poeppel, New York University professor, explains why some songs are likely to stick in you mind than others.

  • Health care and life sciences lead Merck's lifted full-year guidance

    Marcus Kuhnert, the chief financial officer of Merck, comments on the company's earnings report and explains which areas of the business are doing well.

  • HIV virus in an image taken with transmission electron microscopy.

    A judge ruled that an HIV pill to prevent infection could be funded by the U.K.'s state health service, in a victory for AIDS campaigners.

  • Is DNA analysis worth it?

    Should sporting professionals, academics or even the average individual get their genetic data analyzed? CNBC investigates.

  • The Athlome Project: Setting its sights on a world record

    The Athlome project is an international joint effort to identify performance genes and genes that may influence the injury and predisposition to injury and illness.

  • Training to be a Olympic champion

    How does World Olympic champion, Greg Rutherford get ready for important sports events and what did his DNA results show? CNBC takes a look.